Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. End Use
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1.1. Commodity flow analysis (Model 1)
1.6.1.2. Approach 1: Commodity flow approach
1.6.1.3. Volume price analysis (Model 2)
1.6.1.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. I.V. Dressing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing cases of blood infections such as CLABSI and CRBSI
3.2.1.2. Increasing hospital admission
3.2.2. Market restraint analysis
3.2.2.1. Complications associated with I.V. dressing
3.3. I.V. Dressing Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. I.V. Dressing: Type Estimates & Trend Analysis
4.1. I.V. Dressing Market: Type Movement Analysis
4.1.1. Transparent
4.1.1.1. Transparent market estimates and forecast, 2018 – 2030
4.1.2. Translucent
4.1.2.1. Translucent market estimates and forecast, 2018 – 2030
Chapter 5. I.V. Dressing: End-use Estimates & Trend Analysis
5.1. I.V. Dressing Market: End-use Movement Analysis
5.1.1. Hospitals
5.1.1.1. Hospitals market estimates and forecast 2018 to 2030, (USD million)
5.1.2. Clinics
5.1.2.1. Clinics Institutes market estimates and forecast 2018 to 2030, (USD Million)
5.1.3. Others
5.1.3.1. Others market estimates and forecast 2018 to 2030, (USD million)
Chapter 6. I.V. Dressing Market: Regional Estimates & Trend Analysis
6.1. Global Regional Market Snapshot
6.2. North America
6.2.1. North America Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. Competitive Scenario
6.2.2.4. U.S. Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Canada Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.3. Europe
6.3.1. Europe Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Competitive Scenario
6.3.2.4. UK Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Germany Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. France Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Italy Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Spain Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Denmark Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Sweden Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Norway Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.4. Asia Pacific
6.4.1. Asia Pacific Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.4.2. China
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Competitive Scenario
6.4.2.4. China Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.4.3. Japan
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Japan Market estimates and forecast, 2018 – 2030 (Volume, Thousand)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. India Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Australia Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.4.6. Thailand
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Thailand Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.4.7. South Korea
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. South Korea Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.5. Latin America
6.5.1. Latin America Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Competitive Scenario
6.5.2.4. Brazil Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.5.3. Mexico
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Mexico Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.5.4. Argentina
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Argentina Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.6. MEA
6.6.1. MEA Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.6.2. Saudi Arabia
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Competitive Scenario
6.6.2.4. Saudi Arabia Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. South Africa Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. UAE Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Kuwait Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Innovators
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2022
7.3.4. 3M
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. RICHARDSON HEALTHCARE, INC.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. MEDLINE INDUSTRIES
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. SMITH & NEPHEW
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. CARDINAL HEALTH
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. CONVATEC GROUP PLC
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. PAUL HARTMANN AG
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. LOHMANN & RAUSCHER (L&R)
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. MCKESSON CORPORATION
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. MOLNLYCKE HEALTH CARE AB
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. DERMARITE INDUSTRIES, LLC
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
7.3.15. DEROYAL INDUSTRIES, INC.
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Product benchmarking
7.3.15.4. Strategic initiatives
7.3.16. BSN MEDICAL
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Product benchmarking
7.3.16.4. Strategic initiatives
7.3.17. DYNAREX CORPORATION.
7.3.17.1. Company overview
7.3.17.2. Financial performance
7.3.17.3. Product benchmarking
7.3.17.4. Strategic initiatives
7.3.18. KOMAL HEALTH CARE PVT. LTD.
7.3.18.1. Company overview
7.3.18.2. Financial performance
7.3.18.3. Product benchmarking
7.3.18.4. Strategic initiatives
7.3.19. SENTRY MEDICAL
7.3.19.1. Company overview
7.3.19.2. Financial performance
7.3.19.3. Product benchmarking
7.3.19.4. Strategic initiatives
7.3.20. SHANDONG DERMCOSY MEDICAL CO.,LTD.
7.3.20.1. Company overview
7.3.20.2. Financial performance
7.3.20.3. Product benchmarking
7.3.20.4. Strategic initiatives
|